Cathie Wood Bought This Stock After Its 27% Drop. Should You?

"Buy when there's blood in the streets," was something famous banker Baron Rothschild once advised, suggesting the time to invest is when everyone else is fleeing a particular asset or the market in general. And superstar investor Cathie Wood did just that last week when she added to her holding of (NASDAQ: MRNA), buying shares for both her flagship Ark Innovation fund and her Ark Genomic Revolution fund. Moderna stock crashed 27% in one trading session after the company lowered its full-year revenue forecast.

Wood, the CEO of Ark Invest, is known for her contrarian growth picks, snapping up future winners when they're trading at bargain levels. The idea is to get in on promising innovators before the crowd -- and reap the rewards over time. Now, Wood is betting on Moderna's ability to overcome recent challenges and become a multiproduct company delivering billion-dollar earnings down the road. Should you follow her into this bet? Let's find out.

Image source: Getty Images.

Continue reading


Source Fool.com